CY1121105T1 - Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv - Google Patents
Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hivInfo
- Publication number
- CY1121105T1 CY1121105T1 CY181101050T CY181101050T CY1121105T1 CY 1121105 T1 CY1121105 T1 CY 1121105T1 CY 181101050 T CY181101050 T CY 181101050T CY 181101050 T CY181101050 T CY 181101050T CY 1121105 T1 CY1121105 T1 CY 1121105T1
- Authority
- CY
- Cyprus
- Prior art keywords
- atazanavir
- combisstatis
- pharmaceutical form
- hiv treatment
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Παρουσιάζονται φαρμακοτεχνικές μορφές των HIV ενώσεων αταζαναβίρης και κομπισιστάτης και μέθοδοι θεραπείας χρησιμοποιώντας αυτές τις φαρμακοτεχνικές μορφές.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361887574P | 2013-10-07 | 2013-10-07 | |
PCT/US2014/059310 WO2015054133A1 (en) | 2013-10-07 | 2014-10-06 | Hiv treatment formulation of atazanavir and cobicistat |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121105T1 true CY1121105T1 (el) | 2019-12-11 |
Family
ID=51743576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181101050T CY1121105T1 (el) | 2013-10-07 | 2018-10-18 | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv |
Country Status (27)
Country | Link |
---|---|
US (2) | US20160038502A1 (el) |
EP (2) | EP3054926B1 (el) |
JP (2) | JP6574415B2 (el) |
KR (1) | KR102286386B1 (el) |
CN (1) | CN106029058A (el) |
AU (1) | AU2014332200B2 (el) |
BR (1) | BR112016007526A8 (el) |
CA (1) | CA2926650A1 (el) |
CL (1) | CL2016000787A1 (el) |
CY (1) | CY1121105T1 (el) |
DK (2) | DK3054926T3 (el) |
EA (1) | EA031172B1 (el) |
ES (2) | ES2927484T3 (el) |
HR (2) | HRP20221126T1 (el) |
HU (1) | HUE059757T2 (el) |
IL (1) | IL244881B (el) |
LT (2) | LT3054926T (el) |
MX (1) | MX368268B (el) |
MY (1) | MY178960A (el) |
PE (1) | PE20160596A1 (el) |
PL (2) | PL3054926T3 (el) |
PT (2) | PT3054926T (el) |
RS (2) | RS57882B1 (el) |
SA (1) | SA516370891B1 (el) |
SG (1) | SG11201602501VA (el) |
SI (2) | SI3421033T1 (el) |
WO (1) | WO2015054133A1 (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130203759A1 (en) * | 2010-04-09 | 2013-08-08 | Faranak Nikfar | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT |
BR112018008651A2 (pt) * | 2015-10-30 | 2018-10-30 | Cancer Prevention Pharmaceuticals Inc | formulação de combinação de dose fixa de eflornitina e sulindaco |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
US20190175511A1 (en) * | 2016-08-08 | 2019-06-13 | Hetero Labs Limited | A Multi-Class Anti-Retroviral Composition |
US11045423B2 (en) | 2016-08-08 | 2021-06-29 | Hetero Labs Limited | Anti-retroviral compositions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5558071A (en) * | 1994-03-07 | 1996-09-24 | Combustion Electromagnetics, Inc. | Ignition system power converter and controller |
US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
IL134830A0 (en) * | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
AU2001252201A1 (en) * | 2000-03-14 | 2001-09-24 | Amylin Pharmaceuticals, Inc. | Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
CN104774275A (zh) * | 2006-09-25 | 2015-07-15 | 阿彻-丹尼尔斯-米德兰德公司 | 超吸收性的经表面处理的羧烷基化多糖及其制备方法 |
CN103435570B (zh) | 2007-02-23 | 2015-06-10 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
JP2010530889A (ja) * | 2007-06-22 | 2010-09-16 | ブリストル−マイヤーズ スクイブ カンパニー | アタザナビルを含む錠剤組成物 |
US20130084243A1 (en) * | 2010-01-27 | 2013-04-04 | Liliane Goetsch | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
WO2009084036A2 (en) * | 2007-12-20 | 2009-07-09 | Matrix Laboratories Limited | Composition for treatment of viral infections |
CA2735899A1 (en) * | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
US20110028412A1 (en) * | 2009-08-03 | 2011-02-03 | Cappellos, Inc. | Herbal enhanced analgesic formulations |
US20130203759A1 (en) * | 2010-04-09 | 2013-08-08 | Faranak Nikfar | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT |
-
2014
- 2014-10-06 EP EP14786421.9A patent/EP3054926B1/en active Active
- 2014-10-06 HU HUE18179796A patent/HUE059757T2/hu unknown
- 2014-10-06 SI SI201431985T patent/SI3421033T1/sl unknown
- 2014-10-06 AU AU2014332200A patent/AU2014332200B2/en active Active
- 2014-10-06 LT LTEP14786421.9T patent/LT3054926T/lt unknown
- 2014-10-06 PL PL14786421T patent/PL3054926T3/pl unknown
- 2014-10-06 SG SG11201602501VA patent/SG11201602501VA/en unknown
- 2014-10-06 ES ES18179796T patent/ES2927484T3/es active Active
- 2014-10-06 EP EP18179796.0A patent/EP3421033B1/en active Active
- 2014-10-06 MX MX2016004078A patent/MX368268B/es active IP Right Grant
- 2014-10-06 LT LTEP18179796.0T patent/LT3421033T/lt unknown
- 2014-10-06 DK DK14786421.9T patent/DK3054926T3/en active
- 2014-10-06 US US14/425,443 patent/US20160038502A1/en not_active Abandoned
- 2014-10-06 EA EA201690594A patent/EA031172B1/ru not_active IP Right Cessation
- 2014-10-06 JP JP2016520670A patent/JP6574415B2/ja active Active
- 2014-10-06 PT PT14786421T patent/PT3054926T/pt unknown
- 2014-10-06 RS RS20181143A patent/RS57882B1/sr unknown
- 2014-10-06 KR KR1020167011723A patent/KR102286386B1/ko active IP Right Grant
- 2014-10-06 CN CN201480066184.XA patent/CN106029058A/zh active Pending
- 2014-10-06 CA CA2926650A patent/CA2926650A1/en not_active Abandoned
- 2014-10-06 BR BR112016007526A patent/BR112016007526A8/pt not_active Application Discontinuation
- 2014-10-06 PL PL18179796.0T patent/PL3421033T3/pl unknown
- 2014-10-06 DK DK18179796.0T patent/DK3421033T3/da active
- 2014-10-06 SI SI201430857T patent/SI3054926T1/sl unknown
- 2014-10-06 HR HRP20221126TT patent/HRP20221126T1/hr unknown
- 2014-10-06 MY MYPI2016701258A patent/MY178960A/en unknown
- 2014-10-06 WO PCT/US2014/059310 patent/WO2015054133A1/en active Application Filing
- 2014-10-06 PE PE2016000463A patent/PE20160596A1/es unknown
- 2014-10-06 ES ES14786421.9T patent/ES2693580T3/es active Active
- 2014-10-06 RS RS20220859A patent/RS63570B1/sr unknown
- 2014-10-06 PT PT181797960T patent/PT3421033T/pt unknown
-
2016
- 2016-04-04 IL IL244881A patent/IL244881B/en unknown
- 2016-04-05 CL CL2016000787A patent/CL2016000787A1/es unknown
- 2016-04-07 SA SA516370891A patent/SA516370891B1/ar unknown
-
2018
- 2018-08-30 JP JP2018161767A patent/JP2019011334A/ja active Pending
- 2018-10-03 HR HRP20181582TT patent/HRP20181582T1/hr unknown
- 2018-10-18 CY CY181101050T patent/CY1121105T1/el unknown
-
2019
- 2019-08-07 US US16/534,263 patent/US20190358240A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
CY1123633T1 (el) | Ετεροκυκλικες ενωσεις και οι χρησεις αυτων | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
CY1120529T1 (el) | Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων | |
CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
CL2018000813A1 (es) | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso. | |
DK3142637T3 (da) | Keratin treatment formulations and methods | |
CY1121105T1 (el) | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
MA50541A (fr) | Formulations pharmaceutiques | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
MA42303A (fr) | Formulations pharmaceutiques | |
MA46867A (fr) | Formulations pharmaceutiques | |
MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
MA44987A (fr) | Formulations de médicaments améliorées | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
CY1124057T1 (el) | Διαμορφωτες υποδοχεων χ ηπατος (lxr) | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης |